- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03524989
The Effect of Hyperbaric Oxygen Therapy on Aerobic and Anaerobic Physical Fitness (SPORTRCT)
Study Overview
Status
Intervention / Treatment
Detailed Description
In recent years, several options for physical performance enhancement by increasing blood oxygen content were explored. One option is increasing the number of red blood cells by blood transfusions. Another option is using the erythropoietin hormone. These methods showed an effective increase of maximal oxygen consumption rate (VO2MAX) by 10%. However, due to their inherent risks, the international sports associations banned their uses. A third option of training in high altitude environments, but this option was never proved to be effective.
Another strategy would be increasing the blood oxygen content by increasing the plasma dissolved oxygen concentration. This would only be possible using hyperbaric oxygen therapy -which includes inhaling 100% oxygen in a pressure higher than the normal atmospheric pressure.
Previous evidence showed hyperbaric oxygen can enhance aerobic and anaerobic performance during the exposure. These studies evaluated the effect during a single hyperbaric oxygen exposure. The effect of continuous exposure of hyperbaric oxygen on performance was never evaluated.
The study is designed as a randomized controlled study aiming to evaluate the therapeutic effects of hyperbaric oxygen therapy (HBOT) on the aerobic and anaerobic performance.
After signing an informed consent form, patients will be randomized into 2 groups: treatment and control group. Patients will be invited for baseline evaluations. All patients would be evaluated 2 times - at baseline and after 2 months of follow up, The evaluation will include physical examination, VO2MAX, muscle biopsy for mitochondrial function, aerobic function measurements, cognitive assessment, brain MRI, brain EEG.
Protocols:
Treatment: Patients will receive 40 daily sessions, 5 days/week, 60 minutes each with 5 minutes air break every 30 minutes, 100% oxygen at 2 atmospheres (ATA).
Control: Patients will receive 40 daily sessions, 5 days/week, 60 minutes each with 5 minutes air break every 30 minutes, 21% oxygen (air) at 1.01 ATA.
Upon completion of the study, control group would be offered to crossover and complete additional 40 sessions of 100% oxygen at 2 ATA. A third evaluation would be performed in case patients will complete the protocol.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Ramla, Israel, 70300
- Assaf-Harofeh Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-25 or 40-50 age
- Professional performance of aerobic sports for ages 18-25 (at least 5 times a week)
- Moderate and above performance of aerobic sports for ages 40-50 (at least 4 times a week)
- no chronic illness
- no significant musculoskeletal injury in the past 3 months
Exclusion Criteria:
- Debilitating significant musculoskeletal injury
- Previous hyperbaric oxygen exposure
- Lung pathology
- Middle or Inner ear pathology
- Claustrophobia
- Chronic illness
- Smoking
- Chronic medications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment
Hyperbaric Oxygen Therapy: 2 months of treatment consisting of 40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
|
40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 2 months.
|
Sham Comparator: Control/Crossover
SHAM therapy: 2 months of treatment consisting of 40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week
|
40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week for 2 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline of exercise VO2 MAX at 2 months and 4 months
Time Frame: baseline, at 2 months, 4 months
|
Using a standard exercise test which includes gas analysis, the change in VO2 maxs will be assessed 2 months and 4 months compared to baseline
|
baseline, at 2 months, 4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline of maximal respiratory rate
Time Frame: baseline, at 2 months, at 4 months
|
Using a trucut needle, the gluteus maximus will be sampled in a sterile technique for 1-2mg of muscle tissue.
Oroboros O2k high resolution respirometry analyzer will be used (Oxygraph-2k Oroboros Instruments, Innsbruck, Austria).
Maximal respiration rate (nmol/ml) will be calculated.
|
baseline, at 2 months, at 4 months
|
Change from baseline of basal respiration rate
Time Frame: baseline, at 2 months, at 4 months
|
Using a trucut needle, the gluteus maximus will be sampled in a sterile technique for 1-2mg of muscle tissue.
Oroboros O2k high resolution respirometry analyzer will be used (Oxygraph-2k Oroboros Instruments, Innsbruck, Austria).
Basal respiration rate (nmol/ml) will be measured where mitochondrial reserve capacity and ATP-linked respiration will be calculated.
|
baseline, at 2 months, at 4 months
|
Change from baseline of respiration independent adenosine triphosphate (ATP) production (in muscle biopsy
Time Frame: baseline, at 2 months, at 4 months
|
Using a trucut needle, the gluteus maximus will be sampled in a sterile technique for 1-2mg of muscle tissue.
Oroboros O2k high resolution respirometry analyzer will be used (Oxygraph-2k Oroboros Instruments, Innsbruck, Austria).
Inpendent adenosine triphosphate (ATP) production (proton leak) (nmol/ml) will be calculated.
|
baseline, at 2 months, at 4 months
|
Change from baseline in body fat/muscle ratio
Time Frame: baseline, at 2 months, at 4 months
|
Using an electric current weight, the fat % and muscle % content will be measured.
|
baseline, at 2 months, at 4 months
|
Change in maximal vertical jump (meters)
Time Frame: baseline, at 2 months, at 4 months
|
Maximal running speed, maximal vertical jump height will be measured according the standards.
|
baseline, at 2 months, at 4 months
|
Change in maximal running speed (km/hr)
Time Frame: baseline, at 2 months, at 4 months
|
Maximal running speed will be measured according the standards.
|
baseline, at 2 months, at 4 months
|
Change in forced expiratory volume at one second (FEV1)
Time Frame: baseline, at 2 months, at 4 months
|
Using a standard spirometry, forced expiratory volume at one second (FEV1) (liters/second) will be measured
|
baseline, at 2 months, at 4 months
|
Change in forced volume capacity (FVC)
Time Frame: baseline, at 2 months, at 4 months
|
Using a standard spirometry, forced volume capacity (FVC) (liters/second) will be measured
|
baseline, at 2 months, at 4 months
|
Change in general cognitive function
Time Frame: baseline, at 2 months, at 4 months
|
Patients' cognitive functions will be assessed by Neurotrax computerized cognitive tests to generate the general cognitive index (0-100)
|
baseline, at 2 months, at 4 months
|
Change from baseline of brain blood perfusion in brain MRI
Time Frame: baseline, at 2 months, at 4 months
|
imaging will be performed for evaluation of brain changes and angiogenesis process using MRI perfusion and microstructure
|
baseline, at 2 months, at 4 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 0244-16-ASF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Hyperbaric Oxygen Therapy
-
National Baromedical ServicesMayo Clinic; Dartmouth-Hitchcock Medical Center; Eastern Virginia Medical School and other collaboratorsCompletedCarcinoma, Squamous Cell | Cancer of the Head and NeckUnited States
-
Bayside HealthNational Health and Medical Research Council, Australia; Monash UniversityCompletedTibial Fracture | Soft Tissue InjuryAustralia, Sweden, Chile, United States, Austria, India, Italy, Portugal, Czechia
-
Louisiana State University Health Sciences Center...U.S. Army Medical Research and Development CommandUnknownTraumatic Brain Injury | Post-Concussion SyndromeUnited States
-
Omar AljitawiCompleted
-
University of British ColumbiaUnknown
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
St. Joseph's Healthcare HamiltonUniversity Health Network, Toronto; Judy Dan Research and Treatment Centre...CompletedDiabetes Mellitus | Chronic Ulcers of the Lower LimbCanada
-
University of VersaillesAssistance Publique - Hôpitaux de ParisTerminatedCarbon Monoxide PoisoningFrance
-
UMC UtrechtThe Netherlands Cancer InstituteCompletedBreast Cancer | Radiation ToxicityNetherlands
-
The First Affiliated Hospital of Zhejiang Chinese...Not yet recruitingCOVID-19 | Cognitive Decline | SARS CoV 2 InfectionChina